Pramipexole and Breastfeeding

Summary of use during lactation

No information is available on the use of pramipexole during breastfeeding, but it suppresses serum prolactin and may interfere with breastfeeding. An alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug levels in milk and infant serum

Maternal Levels. Relevant published information was not found as of the revision date. Infant Levels. Relevant published information was not found as of the revision date.

Effects in breastfed infants

Relevant published information was not found as of the revision date.

Effects on lactation and breastmilk

Relevant published information in nursing mothers was not found as of the revision date. Pramipexole lowers serum prolactin.[1-3] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

References

1. Schilling JC, Adamus WS, Palluk R. Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans. Clin Pharmacol Ther 1992;51:541-8.1350237 PubMed
2. Daniel JS, Govindan JP, Kamath C, et al. Newer dopaminergic agents cause minimal endocrine effects in idiopathic Parkinson's disease. Clin Med Insights Endocrinol Diabetes 2014;7:13-7.24855402 PubMed
3. Picchietti DL, Hensley JG, Bainbridge JL, et al. Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation. Sleep Med Rev 2015;22:64-77.25553600 PubMed